

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

ATTORNEY'S DOCKET NUMBER

P20670

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

09/763617

INTERNATIONAL APPLICATION NO.

PCT/EP99/06486

INTERNATIONAL FILING DATE

3 September 1999

PRIORITY DATE CLAIMED

5 September 1998

TITLE OF INVENTION

GABA UPTAKE INHIBITORS HAVING A PYRROLIDINE STRUCTURE

APPLICANT(S) FOR DO/EO/US

Klaus WANNER, Günther FÜLEP, and Georg HÖFNER

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information.

1. ☒ This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to promptly begin national examination procedures (35 U.S.C. 371(f)).
4. ☒ The US has been elected by the expiration of 19 months from the priority date (PCT Article 31).
 - a. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☒ is attached hereto (required only if not communicated by the International Bureau).
 - b. ☒ has been communicated by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
 - b. ☒ An English language translation of the International Application as filed (35 U.S.C. 371 (c)(2)).
5. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ have been communicated by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
6. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3))
7. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
8. ☐ "Unexecuted"
9. ☐ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (U.S.C. 371(c)(5)).

Items 11 to 16 below concern other document(s) or information included:

11. Assignee: BDD BEROLINA DRUG DEVELOPMENT AB of Svedala, SWEDEN
12. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
13. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
14. ☒ A FIRST preliminary amendment.
☐ A SECOND or SUBSEQUENT preliminary amendment.
15. ☐ A substitute specification.
16. ☐ A change of power of attorney and/or address letter.
17. ☐ Figure of Drawing to be published
18. ☒ Other items or information:
Cover Sheet and International Application as published in German.
Cover Letter under 35 USC 371 and 1.495.
Claim of Priority.

09/76361

INTERNATIONAL APPLICATION NO.
PCT/EP99/06486ATTORNEY'S DOCKET NUMBER
P20670

19. The following fees are submitted:

Basic National Fee (37 CFR 1.492(a)(1)-(5)):

Search report has been prepared by the EPO or JPO. \$ 860.00

International preliminary examination fee paid to USPTO (37 CFR 1.482). \$ 690.00

No international preliminary examination fee paid to USPTO (37 CFR 1.482) but
international search fee paid to USPTO (37 CFR 1.445(a)(2)). \$ 710.00Neither international preliminary examination fee (37 CFR 1.482) nor
international search fee (37 CFR 1.445(a)(2)) paid to USPTO. \$1,000.00International preliminary examination fee paid to USPTO (37 CFR 1.482) and all
claims satisfied provisions of PCT Article 33(2)-(4). \$ 100.00

ENTER APPROPRIATE BASIC FEE AMOUNT =

Surcharge of \$130.00 for furnishing the oath or declaration later than 20 30
months from the earliest claimed priority date (37 CFR 1.492(e)).

Claims	Number Filed	Number Extra	RATE		
Total Claims	15 - 20 =	0	X \$18.00	\$0.00	
Independent Claims	1 - 3 =	0	X \$80.00	\$0.00	
Multiple dependent claim(s) (if applicable)			+ \$270.00	\$0.00	

TOTAL OF ABOVE CALCULATIONS = \$860.00

☒ Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced
by 1/2. \$430.00

SUBTOTAL = \$430.00

Processing fee of \$130.00 for furnishing the English translation later than 20 30
months from the earliest claimed priority date (37 CFR 1.492(f)). +

Extension of Time fee in the amount of \$

TOTAL NATIONAL FEE = \$430.00

Fee for recording the enclosed assignment (37 CFR 1.21(h). The assignment must be
accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +

TOTAL FEES ENCLOSED = \$430.00

Amount to be
refunded \$

Charged \$

a. ☒ A check in the amount of \$430.00 to cover the above fees is enclosed.

b. Please charge my Deposit Account No. in the amount of \$ to cover the above fees.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to
Deposit Account No. 19-0082.NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.437(a) or (b)) must be filed and
granted to restore the application to pending status.SEND ALL CORRESPONDENCE TO CUSTOMER NO. 7055
AT THE PRESENT ADDRESS OF:Neil F. Greenblum
GREENBLUM & BERNSTEIN, P.L.C.
1941 Roland Clarke Place
Reston, VA 20191
(703) 716-1191

SIGNATURE

Neil F. Greenblum

NAME

33,098

28,394

REGISTRATION NUMBER

09/763617

JCO Rec'd PCT/PTO 02 MAR 2001

P20670.P02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant :K. WANNER et al.

Serial No :Not Yet Assigned
(U.S. National Phase of PCT/EP99/06486)

Filed :September 3, 1999

For :GABA UPTAKE INHIBITORS HAVING A PYRROLIDINE STRUCTURE

**COVER LETTER ACCOMPANYING U.S. NATIONAL STAGE PATENT
APPLICATION FILED UNDER 35 U.S.C. 371
AND 37 C.F.R. 1.495**

Commissioner of Patents and Trademarks
Washington, D.C. 20231

Sir:

Enclosed is a new National Stage patent application for filing in the U.S. Patent and Trademark Office under 35 U.S.C. 371 and 37 C.F.R. 1.495. The Declaration and Power of Attorney attached thereto are in unexecuted form. A properly executed Declaration and Power of Attorney, will be filed within the period of time set in a Notification to be mailed by the United States Patent and Trademark Office.

Related to this, a correspondence address is provided in
the unexecuted Declaration and Power of Attorney, and is as follows:


GREENBLUM & BERNSTEIN, P.L.C.
1941 Roland Clarke Place
Reston, Va. 20191

09/763617

Rec'd PCT/PTC 02 MAR 2001

If there are any questions pertaining to this National Stage Application, please contact the undersigned below.

Respectfully submitted,
K. WANNER et al.



Neil F. Greenblum
Reg. No. 28,394

March 2, 2001
GREENBLUM & BERNSTEIN, P.L.C.
1941 Roland Clarke Place
Reston, VA 20191
(703) 716-1191

Ex no. 33,094

patent application serial no.

*Department of Commerce
Patent and Trademark Office
fee record*

03/06/2001 UEDUVIJE 00000096 09763617

01 FC:971

430.00 QP